In this video from Eyecelerator @ AAO, Visus Therapeutics CEO Ben Bergo discusses the company’s acquisition of ViewPoint’s patents and how this will help it further develop treatment options for presbyopia and cataracts.

“By this acquisition, we now have a library of compounds to again develop an aggregation inhibitor to address this cataract that can develop, but also presbyopia,” Bergo said.